Zacks Research Issues Negative Estimate for Clorox Earnings

The Clorox Company (NYSE:CLX) – Equities research analysts at Zacks Research decreased their Q3 2026 earnings estimates for shares of Clorox in a research note issued on Tuesday, February 17th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.48 per share for the quarter, down from their previous estimate of $1.55. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q4 2026 earnings at $2.23 EPS, Q2 2027 earnings at $1.56 EPS, Q3 2027 earnings at $1.56 EPS, FY2027 earnings at $6.74 EPS and Q2 2028 earnings at $1.69 EPS.

A number of other research firms have also issued reports on CLX. The Goldman Sachs Group reduced their price target on shares of Clorox from $110.00 to $94.00 and set a “sell” rating for the company in a research report on Wednesday, January 7th. Weiss Ratings cut shares of Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, February 4th. Citigroup boosted their target price on shares of Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. BNP Paribas Exane raised Clorox from an “underperform” rating to a “neutral” rating in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada set a $132.00 price objective on Clorox in a research note on Wednesday, February 4th. One analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clorox has a consensus rating of “Reduce” and a consensus price target of $118.73.

Clorox Trading Up 1.1%

Shares of NYSE:CLX opened at $123.51 on Thursday. The company has a quick ratio of 0.48, a current ratio of 0.74 and a debt-to-equity ratio of 71.03. Clorox has a 52-week low of $96.66 and a 52-week high of $159.04. The stock has a market cap of $14.93 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 0.60 and a beta of 0.59. The business has a 50-day moving average price of $109.75 and a 200-day moving average price of $113.68.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). Clorox had a net margin of 11.17% and a return on equity of 383.01%. The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the firm earned $1.55 earnings per share. Clorox’s quarterly revenue was down .8% compared to the same quarter last year.

Institutional Investors Weigh In On Clorox

Institutional investors have recently modified their holdings of the business. Center for Financial Planning Inc. acquired a new position in Clorox in the 3rd quarter worth about $25,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Clorox in the third quarter valued at approximately $25,000. Total Investment Management Inc. acquired a new position in shares of Clorox during the 2nd quarter worth approximately $25,000. True Wealth Design LLC raised its stake in shares of Clorox by 1,020.0% during the 3rd quarter. True Wealth Design LLC now owns 224 shares of the company’s stock worth $28,000 after buying an additional 204 shares during the period. Finally, NewSquare Capital LLC lifted its position in shares of Clorox by 567.6% during the 2nd quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock valued at $27,000 after buying an additional 193 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Zacks raised its FY2028 EPS view to $7.23 and upgraded select quarterly/annual estimates (including Q1 2028 to $1.37 and Q4 2026/2027 increases), signaling modestly better forward earnings visibility that can support the stock.
• Positive Sentiment: Clorox published a consumer research report “Home Care Redefined” that underscores evolving demand for wellness- and convenience-oriented home-care products — a strategic tailwind for branded consumer staples. Home Care Redefined
• Neutral Sentiment: Management presented at the Consumer Analyst Group of New York (CAGNY) conference; slides and prepared remarks provide more detail on strategy, cost actions and growth initiatives — useful for longer-term positioning but not an immediate earnings surprise. CAGNY Slides Transcript
• Negative Sentiment: Zacks trimmed multiple near-term quarterly EPS forecasts (several Q2–Q3 2026/2027 cuts and FY2027 lowered to $6.74), reflecting caution about near-term volume/mix or cost pressure — a potential headwind for sentiment and short-term guidance expectations.
• Negative Sentiment: Wells Fargo issued a “Hold” on CLX (reported as “receives a Hold”), which keeps sell-side sentiment neutral-to-cautious and may limit near-term upside from upgrades. Wells Fargo Hold

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.